natgillin/translations-raw huggingface dataset:
• This medicinal product must be administered under close medical supervision in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of haemolysis (see section 4.8). 
• Ovaj se lijek mora primjenjivati pod strogim liječničkim nadzorom u bolesnika s nedostatkom glukoza-6-fosfat dehidrogenaze (G6PD) zbog rizika od hemolize (vidjeti dio 4.8).
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Warnings and precautions'). 
Ako ste ipak zabrinuti zbog krvarenja, odmah obavijestite svog liječnika (vidjeti dio 2. „Upozorenja i mjere opreza”).
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%. 
U studiji CAPRIE, u bolesnika koji su se liječili klopidogrelom ili ASK, ukupna incidencija krvarenja iznosila je 9,3%.
A pharmacodynamic interaction between Clopidogrel/Acetylsalicylic acid Mylan and heparin is possible, leading to increased risk of bleeding. 
Farmakodinamička interakcija između lijeka Klopidogrel/acetilsalicilatna kiselina Mylan i heparina je moguća i može povećati rizik od krvarenja.
Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese. 
Učestalost genotipova sporih CYP2C19 metabolizatora prema objavljenim podacima iznosi otprilike 2% za bijelce, 4% za crnce i 14% za Kineze.
Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk. 
Specifične farmakokinetičke studije provedene s radioaktivno označenim klopidogrelom pokazale su da se ishodišni spoj klopidogrel ili njegovi metaboliti izlučuju u mlijeko.
As with other oral P2Y12 inhibitors, co-administration of opioid agonists has the potential to delay and reduce the absorption of clopidogrel presumably because of slowed gastric emptying. 
Kao i kod drugih oralnih P2Y12 inhibitora, istodobna primjena agonista opioida može potencijalno odgoditi i smanjiti apsorpciju klopidogrela, pretpostavlja se zbog usporenog želučanog pražnjenja.
A total of 99.7% of patients received fibrinolytics (fibrin-specific: 68.7%, non-fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins. 
Fibrinolitike je primalo 99,7% bolesnika (fibrin-specifični: 68,7%, fibrin-nespecifični: 31,1%), 89,5% heparin, 78,7% beta blokatore, 54,7% ACE inhibitore i 63% statine.
The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers. 
CYP2C19*2 i CYP2C19*3 aleli čine većinu alela sa smanjenom funkcijom u sporih metabolizatora u bijelaca (85%) i Azijata (99%).
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450. 
In vitro i in vivo, klopidogrel se metabolizira kroz dva glavna metabolička puta: jedan posredovan esterazama, koji dovodi do hidrolize u neaktivni derivat karboksilne kiseline (koji čini 85% cirkulirajućih metabolita) i drugi posredovan s više enzima citokroma P450.
C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. 
C radioaktivno označenog klopidogrela u ljudi, otprilike 50% doze se izlučuje u urinu te otprilike 46% u fecesu u razdoblju od 120 sati nakon doziranja.
Gastrointestinal and retroperitoneal haemorrhage with fatal outcome, pancreatitis. 
Gastrointestinalna i retroperitonealna krvarenja sa smrtnim ishodom, pankreatitis.
The tablets are provided in blister packs of 28 or 30 tablets or perforated unit dose blister packs of 28 or 30 tablets or plastic bottles of 100 tablets. 
Tablete su dostupne u blisterima s 28 ili 30 tableta ili perforiranim blisterima s jediničnim dozama s 28 ili 30 tableta ili plastičnim bocama sa 100 tableta.
The use of clopidogrel in CURE was associated with a decrease in the need for thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%). 
Primjena klopidogrela u studiji CURE bila je povezana sa smanjenjem potrebe za trombolitičkom terapijom (RRR=43,3%; CI: 24,3%; 57,5%) i inhibitorima GPIIb/IIIa (RRR=18,2%; CI: 6,5%;
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity. 
Klopidogrel je testiran u različitim in vitro i in vivo studijama genotoksičnosti te nije pokazao genotoksičnu aktivnost.
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised. 
Preporučuje se nadzirati znakove preosjetljivosti u bolesnika s poznatom alergijom na tienopiridine.
Clopidogrel plus ASA significantly reduced the relative risk of death from any cause by 7% (p = 0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p = 0.002), representing an absolute reduction of 0.5% and 0.9%, respectively. 
Kombinacija klopidogrela plus ASK značajno je smanjila relativni rizik od smrti zbog bilo kojeg uzroka za 7% (p=0,029) i relativni rizik kombinacije ponovljenog infarkta, moždanog udara ili smrti za 9% (p=0,002), što predstavlja apsolutno smanjenje od 0,5%, odnosno 0,9%.
• signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots, and/or confusion (see section 2 ‘Warnings and precautions'). 
• znakove jetrenih tegoba kao što su žuta boja kože i/ili očiju (žutica), bez obzira jesu li povezani s krvarenjem koje se pojavljuje kao crvene točkice ispod kože i/ili zbunjenošću (vidjeti dio 2. „Upozorenja i mjere opreza”);
If you stop taking Clopidogrel/Acetylsalicylic acid Mylan Do not stop the treatment unless your doctor tells you so. 
Ako prestanete uzimati lijek Klopidogrel/acetilsalicilatna kiselina Mylan Ne prekidajte liječenje osim ako Vam to ne savjetuje liječnik.
In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in reproductive toxicity (see section 5.3). 
Primjena inhibitora sinteze prostaglandina u životinja, rezultirala je reproduktivnom toksičnošću (vidjeti dio 5.3).
Clopidogrel has been evaluated for safety in more than 42,000 patients who have participated in clinical studies, including over 30,000 patients treated with clopidogrel plus ASA, and over 9,000 patients treated for 1 year or more. 
Sigurnost primjene klopidogrela procijenjena je na više od 42 000 bolesnika koji su sudjelovali u kliničkim ispitivanjima, uključujući više od 30 000 bolesnika liječenih kombinacijom klopidogrela plus ASK te više od 9000 bolesnika koji su lijek primali godinu ili više dana.
Cellulose microcrystalline Lactose 
Mikrokristalična celuloza Laktoza
Although the clinical relevance of these findings is uncertain, there have been spontaneous reports of HIV-infected patients treated with boosted ART, who have experienced re-occlusive events after de-obstruction or have suffered thrombotic events under a clopidogrel loading treatment schedule. 
Iako klinička važnost ovih otkrića nije jasna, postoji više spontanih izvješća bolesnika zaraženih virusom HIV liječenih pojačanim lijekovima ART koji su imali reokluzije nakon uklanjanja opstrukcije ili trombotičke događaje kod liječenja uz održavanje doze klopidogrela.
Proton Pump Inhibitors (PPI) 
Inhibitori protonske pumpe (IPP)
the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labour. 
• majku i novorođenčad, pri kraju trudnoće: - mogućem produljenju vremena krvarenja, antitrombocitnom učinku koji se može pojaviti već pri vrlo niskim dozama; - inhibiciji kontrakcije maternice što za ishod može imati odgođeni ili produljeni porod.
Clopidogrel/Acetylsalicylic acid Mylan is not recommended in this population. 
Klopidogrel/acetilsalicilatna kiselina Mylan ne preporučuje se za ovu populaciju.
Acetylsalicylic acid (ASA): 
Acetilsalicilatna kiselina (ASK):
The cumulative incidence of all bleeding events (BARC class 1 to 5) was 9% (114 events) in the guided deescalation group versus 11% (137 events) in the control group (p=0.14). 
Kumulativna incidencija svih događaja krvarenja (BARC stupanj krvarenja od 1 do 5) bila je 9% (114 događaja) u skupini s vođenom de-eskalacijom u odnosu na 11% (137 događaja) u kontrolnoj skupini (p=0,14).
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles correspond to non-functional metabolism. 
CYP2C19*1 alel odgovara potpuno funkcionalnom metabolizmu, dok se CYP2C19*2 i CYP2C19*3 aleli povezuju s nefunkcionalnim metabolizmom.
Exposure of clopidogrel and average platelet inhibition can be decreased with concomitant use of ritonavir. 
Izloženost klopidogrelu i prosječna inhibicija trombocita može se umanjiti istodobnom primjenom ritonavira.
Activated charcoal (adsorbent) and sodium sulphate (laxative) are then administered. 
Nakon toga primjenjuju se aktivni ugljen (adsorbens) i natrijev sulfat (laksativ).
In a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss. 
U jednom kliničkom ispitivanju sa zdravim dobrovoljcima, istodobna primjena klopidogrela i naproksena povećala je gastrointestinalno okultno krvarenje.
The safety and efficacy of clopidogrel plus ASA have been evaluated in three double-blind studies involving over 61,900 patients: the CURE, CLARITY and COMMIT studies, comparing clopidogrel plus ASA to ASA alone, both treatments given in combination with other standard therapy. 
Sigurnost primjene i djelotvornost klopidogrela plus ASK procijenjeni su u tri dvostruko slijepe studije koje su uključivale preko 61 900 bolesnika: CURE, CLARITY i COMMIT studije, u kojima se uspoređivalo djelovanje klopidogrela plus ASK prema samoj ASK, s tim da su obje terapije davane u kombinaciji s drugim standardnim terapijama.
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics). 
Prevalencija CYP2C19 alela koji rezultiraju intermedijarnim i sporim CYP2C19 metabolizmom razlikuje se prema rasi/etničkoj skupini (vidjeti dio „Farmakogenetika”).
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed, blood in the urine. 
Krvarenje se može pojaviti u obliku krvarenja u želucu ili crijevima, stvaranja modrica, hematoma (neuobičajeno krvarenje ili stvaranje modrica ispod kože), krvarenja iz nosa, krvi u mokraći.
Cases of Reye's syndrome have occurred following the use of salicylates during varicella infections (see section 4.4). 
Slučajevi Reyeva sindroma javili su se nakon primjene salicilata tijekom infekcije uzročnikom varičela (vidjeti dio 4.4).
In a small number of cases, bleeding in the eye, inside the head (especially in elderly), the lung or the joints has also been reported. 
U malom broju slučajeva, zabilježena su krvarenja u oku, glavi (osobito u starijih osoba), plućima ili zglobovima.
Clopidogrel was found to have no effect on the fertility of male and female rats and was not teratogenic in either rats or rabbits. 
Klopidogrel nije imao štetnih učinaka na fertilitet mužjaka i ženki štakora te nije pokazao teratogene učinke na štakorima i kunićima.
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8). 
Zbog rizika od krvarenja i hematoloških nuspojava, potrebno je odmah provjeriti krvnu sliku i/ili napraviti druge odgovarajuće pretrage kad god se tijekom liječenja pojave klinički simptomi koji ukazuju na krvarenje (vidjeti dio 4.8).
No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultra-rapid, extensive and intermediate metabolisers. 
Nisu opažene značajne razlike u izloženosti aktivnom metabolitu i srednjoj vrijednosti inhibicije agregacije trombocita (IPA, engl. inhibition of platelet aggregation) među vrlo brzim, brzim i intermedijarnim metabolizatorima.
These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes. 
Te promjene su se javljale pri dozama koje su bile najmanje 25 puta veće od izloženosti u ljudi koji su primali kliničku dozu od 75 mg klopidogrela na dan i bile su posljedice učinka na jetrene metaboličke enzime.
• if you suffer from severe liver disease. 
• ako patite od teške bolesti jetre,
• if you have a medical condition that includes the combination of asthma, nasal discharge (runny nose) and polyps (a type of growth in the nose). 
• ako imate stanje koje uključuje kombinaciju astme, curenja iz nosa i polipe (vrsta izraslina u nosu),
• Severe renal impairment (creatinine clearance <30 ml/min). 
• kod teškog oštećenja funkcije bubrega (klirens kreatinina< 30 ml/min),
Due to the presence of both components of the medicinal product, Clopidogrel/Acetylsalicylic acid Mylan is contraindicated in case of: 
Zbog prisutnosti dvije djelatne tvari u lijeku, Klopidogrel/acetilsalicilatna kiselina Mylan je kontraindicirana u slučaju:
The guided de-escalation did not result in an increased combined risk of ischemic events (2.5% in the deescalation group vs 3.2% in the control group; p non-inferiority=0.0115), nor in the key secondary endpoint of BARC bleeding ≥2 ((5%) in the de-escalation group versus 6% in the control group (p=0.23)). 
Vođena de-eskalacija nije rezultirala povećanjem u kombiniranom riziku od ishemijskih događaja (2,5% u skupini s vođenom de-eskalacijom u odnosu na 3,2% u kontrolnoj skupini; p neinferiornosti=0,0115) niti u ključnoj sekundarnoj mjeri ishoda BARC stupnja krvarenja ≥ 2 ((5%) u skupini s vođenom de-eskalacijom nasuprot 6% u kontrolnoj skupini (p=0,23)).
• In patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Qwave myocardial infarction): The optimal duration of treatment has not been formally established. 
• U bolesnika s akutnim koronarnim sindromom bez elevacije ST-segmenta (nestabilna angina ili non-Q- infarkt miokarda): optimalno trajanje liječenja još nije formalno utvrđeno.
The desiccant should not be eaten. 
Sredstvo za sušenje se ne smije progutati.
Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies. 
Prijavljeni podaci iz opservacijskih i kliničkih studija o kliničkim implikacijama ove farmakokinetičke (PK)/farmakodinamičke (PD) interakcije u smislu velikih kardiovaskularnih događaja su nekonzistentni.
Kounis syndrome (vasospastic allergic angina / allergic myocardial infarction) in the context of a hypersensitivity reaction due to acetylsalicylic acid* or clopidogrel** 
Kounisov sindrom (alergijska vazospastična angina / alergijski infarkt miokarda) u kontekstu reakcije preosjetljivosti na acetilsalicilatnu kiselinu* ili klopidogrel**
Where elective surgery is being considered, the need for dual antiplatelet therapy should be reviewed and consideration given to the use of a single antiplatelet agent. 
Ako se razmatra elektivni kirurški zahvat, potrebno je ponovno razmotriti potrebu za terapijom dvostrukim antitrombocitnim lijekom te treba uzeti u obzir mogućnost liječenja pojedinačnim antitrombocitnim lijekom.
The concomitant administration of salicylates and valproic acid may result in decreased valproic acid protein binding and inhibition of valproic acid metabolism resulting in increased serum levels of total and free valproic acid. 
Istodobna primjena salicilata i valproatne kiseline može uzrokovati smanjeno vezanje valproatne kiseline na proteine i inhibiciju metabolizma valproatne kiseline, što dovodi do povećanih vrijednosti ukupne i slobodne valproatne kiseline u serumu.
Apart from the specific medicinal product interaction information described above, interaction studies with Clopidogrel/Acetylsalicylic acid Mylan and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed. 
Osim gore opisanih specifičnih interakcija, nisu provedena ispitivanja interakcija lijeka Klopidogrel/acetilsalicilatna kiselina Mylan s drugim lijekovima koji se obično propisuju bolesnicima s aterotrombotskim bolestima.
Given that children, infants and toddlers are often only seen at a late stage of intoxication, they will usually have already reached the acidosis stage. 
U djece i novorođenčadi predoziranje se često primijeti tek kasnije, kada je obično već nastupila acidoza.
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen. 
Dodatno, vrijednost IPA iznosila je 32% (24 sata) i 61% (dan 5), što je više nego u sporih metabolizatora koji su primali režim doziranja od 300 mg/75 mg i slično je ostalim skupinama CYP2C19 metabolizatora koje su primale režim od 300 mg/75 mg.
• the varicella vaccine, a medicine used to prevent chickenpox or shingles, within 6 weeks of taking Clopidogrel/Acetylsalicylic acid Mylan, or if you have active chickenpox or shingles infection (see section 2 ‘Children and adolescents'), 
• cjepivo protiv varičela, lijek koji se koristi za prevenciju vodenih kozica ili herpesa zostera, u razdoblju od 6 tjedana nakon uzimanja lijeka Klopidogrel/acetilsalicilatna kiselina Mylan, ili ako trenutno imate aktivnu infekciju vodenih kozica ili herpesa zostera (vidjeti dio 2 „Djeca i adolescenti”),
• if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain. 
• ako imate stanje koje trenutno izaziva krvarenje, kao što je, primjerice, želučani ulkus ili krvarenje u mozgu,
The safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction. 
Sigurnost istodobne primjene klopidogrela, fibrinskih ili afibrinskih specifičnih trombolitika i heparina procijenjena je u bolesnika s akutnim infarktom miokarda.
Excipients with known effect Each film-coated tablet contains 48 mg of lactose. 
Pomoćne tvari s poznatim učinkom Jedna filmom obložena tableta sadrži 48 mg laktoze.
Patients with pre-existing mastocytosis, in whom the use of acetylsalicylic acid may induce severe hypersensitivity reactions (including circulatory shock with flushing, hypotension, tachycardia and vomiting). 
Bolesnici s već postojećom mastocitozom, kod kojih primjena acetilsalicilatne kiseline može izazvati teške reakcije preosjetljivosti (uključujući cirkulatorni šok s navalama crvenila, hipotenzijom, tahikardijom i povraćanjem),
The Cmax of the active metabolite is twice as high following a single 300 mg clopidogrel loading dose as it is after four days of 75 -mg maintenance dose. 
Cmax aktivnog metabolita je dvostruko veći nakon primjene jednokratne udarne doze od 300 mg klopidogrela, u odnosu na primjenu doze održavanja od 75 mg tijekom 4 dana.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible side effects'). 
Ako ste ipak zabrinuti zbog krvarenja, odmah obavijestite svog liječnika (vidjeti dio 4. „Moguće nuspojave”).
No clinical data on exposure to clopidogrel/acetylsalicylic acid during pregnancy are available. 
Nisu dostupni klinički podaci o izloženosti klopidogrelu/acetilsalicilatnoj kiselini tijekom trudnoće.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel/Acetylsalicylic acid Mylan. 
Ako ste trudni ili sumnjate na trudnoću, obavijestite svog liječnika ili ljekarnika prije nego što uzmete lijek Klopidogrel/acetilsalicilatna kiselina Mylan.
In TRITON-TIMI 38 and 3 of the cohort studies (Collet, Sibbing, Giusti) the combined group of patients with either intermediate or poor metaboliser status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers. 
U studiji TRITON-TIMI 38 i 3 kohortne studije (Collet, Sibbing, Giusti), kombinirana skupina bolesnika sa statusom intermedijarnih ili sporih metabolizatora, imala je veću stopu kardiovaskularnih događaja (smrt, infarkt miokarda, i moždani udar) ili tromboze u stentu, u usporedbi s brzim metabolizatorima.
Physicians should remain alert for signs of GI ulceration and bleeding, even in the absence of previous GI symptoms. 
Liječnici trebaju obratiti pozornost na znakove gastrointestinalnih ulceracija i krvarenja, čak i u izostanku navedenih gastrointestinalnih simptoma.
Overdose with ASA/clopidogrel fixed dose combination may be associated with increased bleeding and subsequent bleeding complications due to the pharmacological activity of clopidogrel and ASA. 
Predoziranje s fiksnom kombinacijom ASK/klopidogrel može biti povezano s povećanim krvarenjem i posljedičnim komplikacijama krvarenja zbog farmakološke aktivnosti klopidogrela i ASK.
The following symptoms are associated with moderate intoxication: dizziness, headache, tinnitus, confusion and gastrointestinal symptoms (nausea, vomiting and gastric pain). 
Sljedeći simptomi povezani su s umjerenom intoksikacijom: omaglica, glavobolja, tinitus, konfuzija i gastrointestinalni simptomi (mučnina, povraćanje i bol u želucu).
Other concomitant therapy with ASA Interactions with the following medicinal products have been reported with ASA: 
Prijavljene su interakcije sa sljedećim lijekovima:
Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7-10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover. 
Zbog ireverzibilnog vezanja, izloženi trombociti zahvaćeni su ovim učinkom do kraja svog životnog vijeka (oko 7 - 10 dana), a povrat normalne funkcije trombocita događa se brzinom koja odgovara brzini stvaranja novih trombocita.
• In patients with a history of asthma or allergic disorders since they are at increased risk of hypersensitivity reactions. 
• u bolesnika koji u anamnezi imaju astmu ili alergijske poremećaje, zbog povećanog rizika od razvoja reakcija preosjetljivosti,
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39 % (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers. 
Nakon režima doziranja od 300 mg/75 mg, antitrombocitni odgovor bio je smanjen u sporih metabolizatora sa srednjom vrijednosti IPA (5 µM ADP) od 24% (nakon 24 sata) te 37% (na dan 5), u usporedbi s vrijednostima IPA-e od 39% (24 sata) i 58% (dan 5) za brze metabolizatore te 37% (24 sata) i 60% (dan 5) za intermedijarne metabolizatore.
If you become pregnant while taking Clopidogrel/Acetylsalicylic acid Mylan, consult your doctor immediately as it is recommended not to take Clopidogrel/Acetylsalicylic acid Mylan while you are pregnant. 
Ako zatrudnite za vrijeme uzimanja lijeka Klopidogrel/acetilsalicilatna kiselina Mylan, odmah se posavjetujte s liječnikom, jer nije preporučeno uzimati lijek Klopidogrel/acetilsalicilatna kiselina Mylan za vrijeme trudnoće.